Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Subscribe To Our Newsletter & Stay Updated